Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Living With Type 2 Diabetes

Type 2 Diabetes Symptoms

Type 2 Diabetes Treatment

Fibromyalgia and Diabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

The Risks of Prediabetes

Diabetes Mellitus Type 2 Pathophysiology

Insulin Resistance and Parkinson's Disease

Type 2 Diabetes Screening and Prevention

Type 2 Diabetes Diagnosis

Diabetes in Men versus Women

See more featured articles »

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Vitamin D and Type 2 Diabetes

Insulin Resistance Pathophysiology

What is Diabetes?

Insulin Resistance Diagnosis

Causes of Insulin Resistance

Insulin Resistance Symptoms

Does the Keto Diet Increase the Risk of Diabetes?

Insulin Resistance Treatment

Insulin Medication

What is Insulin Resistance?

Latest Type 2 Diabetes News and Research

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

APOLLO AI learns from 25 billion medical events to predict future disease

APOLLO is a multimodal temporal foundation model trained on 25.2 billion medical events from 7.2 million patients across 33 years of Mass General Brigham records, integrating 28 medical modalities into unified “virtual patient representations.” Across 322 downstream tasks, the model showed strong performance in disease prediction, treatment-response stratification, hospital operations, and patient retrieval, supporting the idea of more computable, data-driven medicine.

23 Apr 2026

Vitamin D may prevent diabetes in people with certain genes

More than two in five U.S. adults has prediabetes, a condition marked by higher-than-normal blood sugar levels that often leads to type 2 diabetes.

23 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

High-fat, low-carbohydrate diet may improve beta-cell function in patients with type 2 diabetes

People with type 2 diabetes on a high-fat, low-carbohydrate diet may have a better chance of reversing their diabetes than those on a low-fat diet, according to a small study published in the Journal of the Endocrine Society.

21 Apr 2026

Why heart risk is hard to predict in type 1 diabetes

A European study reveals cardiovascular risk patterns in type 1 diabetes, highlighting the need for tailored prevention strategies to catch complications early.

20 Apr 2026

Eating oranges daily may shift lipid patterns in fatty liver disease

A 4-week trial on 'Navelina' oranges shows potential effects on lipid metabolism in fatty liver disease, revealing intriguing but non-significant patterns.

20 Apr 2026

Obesity, GLP-1s, and metabolic care

An interview with Professor Thomas Forst, Chief Medical Officer, hVIVO

From hVIVO 17 Apr 2026

BMI increases in early childhood may reflect muscle growth, not fat

A new study published in The Journal of Nutrition, a peer-reviewed journal of the American Society for Nutrition, offers new insights into a decades-old puzzle in childhood obesity. The study found that while body mass index (BMI) starts to rise in early childhood during a stage known as adiposity rebound, when BMI increases after an initial decline, the waist-to-height ratio, a measure that better reflects body fat, continues to drop. This suggests that the BMI increase at this age mainly reflects growth in lean tissues such as muscle and bone, rather than extra body fat.

16 Apr 2026

Ultra-processed foods linked to higher obesity risk in adolescents

Adolescents who consume more ultra-processed foods (UPFs) have significantly higher odds of being overweight or obese, according to a new systematic review and meta-analysis published in the open-access journal PLOS One by Mekuriaw Nibret Aweke of the University of Gondar, Ethiopia, and colleagues.

15 Apr 2026

Gut-liver changes drive foodborne infection severity in fatty liver disease

A research team led by the University of California, Irvine's Joe C. Wen School of Population & Public Health has uncovered a critical biological link explaining why individuals with metabolic dysfunction–associated steatotic liver disease (MASLD), or fatty liver disease, face significantly worse outcomes from certain foodborne infections.

15 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Gaining weight before age 30 tied to higher mortality

The study reveals that weight gain before 30 years is associated with increased mortality risk, underscoring the need for early obesity intervention strategies.

15 Apr 2026

Metabolic syndrome doubles worldwide over two decades

A global study reveals a sharp rise in metabolic syndrome prevalence from 2000 to 2023, highlighting urgent public health challenges and regional disparities.

15 Apr 2026

Waist-to-height ratio outperforms BMI in predicting hypertension risk

New waist-to-height cut-offs to assess fat mass and obesity predicted the risk of hypertension better than body mass index, according to a new study from the University of Eastern Finland and the Robert Wood Johnson Medical School at Rutgers University in the US.

14 Apr 2026

Study identifies new genes linked to severe pregnancy sickness

The USC research team that recently identified the hormone-encoding gene GDF15 as a key driver of pregnancy sickness has identified 9 additional genes linked to its most severe form, hyperemesis gravidarum (HG).

14 Apr 2026

Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40 %, in adults in the UK.

From Bayer PLC 13 Apr 2026

Obesity health risks differ significantly between men and women

New research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May), reveals distinct patterns of heart, metabolic, and inflammatory health risks between men and women living with obesity, providing an insight into how clinicians may be able to tailor management approaches.

13 Apr 2026

Genetic variants may reduce effectiveness of popular diabetes drugs

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

12 Apr 2026